ICER’s budget impact threshold: Sounding a false alarm on affordability and access
By Randy Burkholder | July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?
Read More
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
By Holly Campbell | July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....
Read More
How ICER’s assessment of a new class of migraine treatments fails patients
By Lauren Neves | July 10, 2018
Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their...
Read More
Aspen Spotlight Health: Discussing the forefront of innovation
By Katie Koziara | June 21, 2018
For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...
Read More
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
By Randy Burkholder | June 1, 2018
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative...
Read More
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
By Lauren Neves | May 31, 2018
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a ...
Read More
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
By Joe Vandigo | May 29, 2018
A recent study conducted by the Academy of Managed Care Pharmacy (AMCP) and Xcenda found that 71 percent of insurers and 63 percent of biopharmaceutical companies surveyed were interested in...
Read More
By
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic,...
Read More
Reality check: Value-based contracts are good for patients
By Michelle Drozd | April 25, 2018
Biopharmaceutical companies are joining stakeholders across the health care system to pursue flexible ways to pay for medicines that focus on results, lower out-of-pocket costs and enable patients...
Read More
Video: Barriers to results-based contracts
By Katie Koziara | April 17, 2018
Research suggests results-based contracts (RBCs)—also known as value-based contracts—have the potential to lower costs for patients and the health system. According to a recent analysis, these...
Read More
Medicare Monday (100)
340B Spotlight (36)
Cost & Consequence (0)
